1-6 of 6
Yang Feng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

miR-196b–TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML

Holly A. Gamlen, Jennifer S. Romer-Seibert, Michael E. Lawler, Amanda M. Versace, Melanie L. Goetz, Yang Feng, Olga A. Guryanova, Neil Palmisiano, Sara E. Meyer
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4574–4586.
https://doi.org/10.1158/1078-0432.CCR-22-1598
Published: 14 October 2022
View article titled, miR-196b–TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in <em>DNMT3A</em>-Mutant AML
Open the PDF for miR-196b–TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in <em>DNMT3A</em>-Mutant AML in another window
Includes: Supplementary data
Journal Articles

DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Kartika Venugopal, Yang Feng, Pawel Nowialis, Huanzhou Xu, Daniil E. Shabashvili, Cassandra M. Berntsen, Prabhjot Kaur, Kathryn I. Krajcik, Christina Taragjini, Zachary Zaroogian, Heidi L. Casellas Román, Luisa M. Posada, Chamara Gunaratne, Jianping Li, Daphné Dupéré-Richer, Richard L. Bennett, Santhi Pondugula, Alberto Riva, Christopher R. Cogle, Rene Opavsky, Brian K. Law, Sumita Bhaduri-McIntosh, Stefan Kubicek, Philipp B. Staber, Jonathan D. Licht, Jonathan E. Bird, Olga A. Guryanova
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 756–769.
https://doi.org/10.1158/1078-0432.CCR-21-2863
Published: 15 February 2022
View article titled, DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
Open the PDF for DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks in another window
Includes: Supplementary data
Journal Articles

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Nathan M. Kendsersky, Jarrett Lindsay, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher, Stephen W. Erickson, Eric J. Earley, Yael P. Mosse, Daniel Martinez, Jennifer Pogoriler, Kateryna Krytska, Khushbu Patel, David Groff, Matthew Tsang, Samson Ghilu, Yifei Wang, Steven Seaman, Yang Feng, Brad St. Croix, Richard Gorlick, Raushan Kurmasheva, Peter J. Houghton, John M. Maris
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2938–2946.
https://doi.org/10.1158/1078-0432.CCR-20-4221
Published: 15 May 2021
View article titled, The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models
Open the PDF for The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models in another window
Includes: Supplementary data
Journal Articles

Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence

Sneha Ramakrishna, Steven L. Highfill, Zachary Walsh, Sang M. Nguyen, Haiyan Lei, Jack F. Shern, Haiying Qin, Ira L. Kraft, Maryalice Stetler-Stevenson, Constance M. Yuan, Jennifer D. Hwang, Yang Feng, Zhongyu Zhu, Dimiter Dimitrov, Nirali N. Shah, Terry J. Fry
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (17): 5329–5341.
https://doi.org/10.1158/1078-0432.CCR-18-3784
Published: 03 September 2019
View article titled, Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence
Open the PDF for Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer

Cynthia X. Ma, Vera Suman, Matthew P. Goetz, Donald Northfelt, Mark E. Burkard, Foluso Ademuyiwa, Michael Naughton, Julie Margenthaler, Rebecca Aft, Richard Gray, Amye Tevaarwerk, Lee Wilke, Tufia Haddad, Timothy Moynihan, Charles Loprinzi, Tina Hieken, Erica K. Barnell, Zachary L. Skidmore, Yan-Yang Feng, Kilannin Krysiak, Jeremy Hoog, Zhanfang Guo, Leslie Nehring, Kari B. Wisinski, Elaine Mardis, Ian S. Hagemann, Kiran Vij, Souzan Sanati, Hussam Al-Kateb, Obi L. Griffith, Malachi Griffith, Laurence Doyle, Charles Erlichman, Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 6823–6832.
https://doi.org/10.1158/1078-0432.CCR-17-1260
Published: 14 November 2017
View article titled, A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <em>PIK3CA</em>-Mutant ER-Positive and HER2-Negative Breast Cancer
Open the PDF for A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <em>PIK3CA</em>-Mutant ER-Positive and HER2-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Targeting of Bone-Derived Insulin-Like Growth Factor-II by a Human Neutralizing Antibody Suppresses the Growth of Prostate Cancer Cells in a Human Bone Environment

Taichi Kimura, Takeshi Kuwata, Satoshi Ashimine, Manabu Yamazaki, Chisako Yamauchi, Kanji Nagai, Akashi Ikehara, Yang Feng, Dimiter S. Dimitrov, Seiichi Saito, Atsushi Ochiai
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 121–129.
https://doi.org/10.1158/1078-0432.CCR-09-0982
Published: 04 January 2010
View article titled, Targeting of Bone-Derived Insulin-Like Growth Factor-II by a Human Neutralizing Antibody Suppresses the Growth of Prostate Cancer Cells in a Human Bone Environment
Open the PDF for Targeting of Bone-Derived Insulin-Like Growth Factor-II by a Human Neutralizing Antibody Suppresses the Growth of Prostate Cancer Cells in a Human Bone Environment in another window
Includes: Supplementary data